Breastlink has partnered with researchers to explore an investigational cancer immunotherapy called atezolizumab (MPDL3280A) in the treatment of metastatic triple-negative breast cancer. In early-stage trials, atezolizmab was effective in patients previously treated for triple-negative breast cancer. A new trial will investigate atezolizumab with chemotherapy in metastatic triple-negative breast cancer patients who have not received prior systemic therapy for incurable disease.

In true Hollywood fashion, when a celebrity speaks the masses listen.

That’s precisely what happened when Angelina Jolie penned an editorial in The New York Times that shined the spotlight on breast cancer and genetics, specifically genes that can cause the disease.